menu
    • menu
    [{"orgOrder":0,"company":"Ymmunobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"YB-800ADC1","moa":"Tubulin","graph1":"Oncology","graph2":"Preclinical","graph3":"Ymmunobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ymmunobio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ymmunobio \/ Undisclosed"},{"orgOrder":0,"company":"Ymmunobio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"YB-200","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ymmunobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ymmunobio \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Ymmunobio \/ Undisclosed"},{"orgOrder":0,"company":"Ymmunobio","sponsor":"Ymmunobio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"YB-800","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ymmunobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ymmunobio \/ Ymmunobio","highestDevelopmentStatusID":"4","companyTruncated":"Ymmunobio \/ Ymmunobio"}]

    Find Clinical Drug Pipeline Developments & Deals by Ymmunobio

    Menu

    Ymmunobio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ymmunobio

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ymmunobio

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YB-800ADC1

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            YB-800 ADCs Show Proof of Concept in Preclinical Studies

                            Details : YB-800ADC1 and YB-800ADC2, have completed the preclinical proof of concept studies. Both in vivo and in vitro studies have reached this milestone by demonstrating the anti-tumor efficacy of both ADCs.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 18, 2025

                            Lead Product(s) : YB-800ADC1

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ymmunobio

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ymmunobio

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YB-200

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Orphan Drug Designation to Ymmunobio's CEACAM Antibody for the Treatment of Liver Cancer

                            Details : YB-200 belongs to a novel class of CEACAM1 antibodies with a dual action. It acts as a checkpoint inhibitor, but also has a direct immune agonistic effect on immune cells. It is being studying for the treatment of hepatocellular carcinoma (HCC).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 28, 2023

                            Lead Product(s) : YB-200

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ymmunobio

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Ymmunobio

                            Switzerland arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YB-800

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Nagoya University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR Antibodies

                            Details : Under the agreement, Ymmunobio obtained license for the development of YB-800 (NPTXR antibody) which have shown utility for developing therapeutics and for novel diagnostic tools in the treatment of several gastro-intestinal cancers, including gastric ca...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 31, 2023

                            Lead Product(s) : YB-800

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Nagoya University

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth